PureTech Health (GB:PRTC) has released an update.
PureTech Health’s entity, Vor Bio, has revealed promising clinical data from a Phase 1/2 study, indicating that their trem-cel and Mylotarg combination therapy shows potential benefits for patients with relapsed/refractory AML. The treatment demonstrated successful engraftment, protection against Mylotarg toxicity, and a broadened therapeutic window. Additionally, Vor Bio is making progress with a new preclinical asset, VADC45, which could have applications in oncology, gene therapy, and autoimmune diseases.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
